Showing results (81-90 of 233) with videos related to
Sort By:
Pageof 24
Clinical Science and Molecular Medicine. Supplement|June 1, 1975
The use of angiotensin-converting enzyme inhibitor in the diagnosis and treatment of hypertensionH Gavras, H R Brunner, J H Laragh, et al.Agents and Actions. Supplements|January 1, 1987
The antihypertensive contribution of bradykinin as assessed by a specific bradykinin antagonistA Benetos, H Gavras, J M Stewart, et al.Archives of Internal Medicine|November 1, 1977
Is elevated plasma renin activity of prognostic importance in progressive systemic sclerosis?H Gavras, I Gavras, P J Cannon, et al.Clinical and Experimental Hypertension (New York, N.Y. : 1993)|October 1, 1995
Augmentation of coronary blood flow by ACE inhibition: role of angiotensin and bradykininN A Ruocco, B A Bergelson, T K Yu, et al.Current Vascular Pharmacology|August 3, 2013
Sympathetic overactivity in hypertension and cardiovascular diseaseA J Manolis, L E Poulimenos, M S Kallistratos, et al.Clinical and Experimental Hypertension. Part A, Theory and Practice|January 1, 1982
Effects of the new oral angiotensin converting enzyme inhibitor MK-421 in human hypertensionH Gavras, J Biollaz, B Waeber, et al.Lancet (London, England)|September 12, 1981
Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421"H Gavras, J Biollaz, B Waeber, et al.Hypertension (Dallas, Tex. : 1979)|November 1, 1986
Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonistA Benetos, H Gavras, J M Stewart, et al.Hypertension (Dallas, Tex. : 1979)|February 4, 1999
Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertensionK P Makaritsis, D E Handy, C Johns, et al.Hypertension (Dallas, Tex. : 1979)|November 1, 1995
Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategyA J Manolis, C Olympios, M Sifaki, et al.Pageof 24